Archive for the ‘News’ Category

Anaeropharma has presented at 20th JFCR-ISCC (Japanese Foundation for Cancer Research-International Symposium on Cancer Chemotherapy)

At 20th JFCR-ISCC held in December 2015, Anaeropharma has presented its progress on immune checkpoint blocker producing B. longum which titled in “i-DPS (in situ Delivery and Production System): A “smart” Drug Delivery System to Produce Immune Checkpoint Blockers inside Hypoxic Tumor”.

Anaeropharma has presented at BioJapan2015

Anaeropharma has presented its technology platform at BioJapan2015 held in October.

Anaeropharma has presented at JCA (Japanese Cancer Association) Annual Meeting 2015

Anaeropharma has presented its recent research progress which titled in “In situ Delivery and Production System (i-DPS) of Immune Checkpoint Blockers Targeting Tumor Microenvironment” at the annual meeting of JCA held in October, 2015.

Anaeropharma has presented at AACR (American Association for Cancer Research) Annual Meeting 2015

At the annual meeting of AACR held in April 2015, Anaeropharma has presented two posters as follows; 1. In situ delivery and production of anti-HER2 scFv, poster #290. 2. Novel delivery system to bring immune checkpoint antibodies to tumor microenvironment, poster #282.

Presenting our latest research updates at PEGS2014 poster sessions

We are presenting our latest research updates at PEGS2014 poster sessions. PEGS2014 is scheduled to be held in Boston, MA from May 5-9, 2014.

Click here for detail.

Initiated First-in-Human Trial of Novel Recombinant Bifidobacterial Anti-cancer Agent APS001F for Advanced Solid Tumors

We have initiated a Phase I clinical trial of APS001F in patients with advanced solid tumors in the United States. The first-in-human dose-escalation trial enrolls patients with advanced and/or metastatic solid tumors whose disease is no longer considered responsive to available treatments. The trial is designed to evaluate safety, tolerability and efficacy of the study agent.


We have updated Research Overview Page

see here for detail.

We have updated Research Overview page.

see here for detail.

We have moved to our new office

See here for detail.

INCJ determined on up to 2.2 billion yen follow-on investment

Innovation Network Corporation of Japan (INCJ) has determined on a follow-on investment of up to 2.2 billion yen in Anaeropharma.  INCJ has made its initial investment of 700 million yen in November 2010.